| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From The Clinical Research Centers |
Center on Aging and Division of Endocrinology and Metabolism, University of Connecticut Health Center (K.M.P., L.G.R.), Farmington, Connecticut 06030; Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center (M.G.), Portland, Oregon 97201; Lilly Research Laboratories, Eli Lilly & Co. (D.B.M., Y.L., M.W.), Indianapolis, Indiana 46285
Address all correspondence and requests for reprints to: Karen M. Prestwood, M.D., Center on Aging, University of Connecticut Health Center, Farmington, Connecticut 06030-5215. E-mail: prestwood{at}nso1.uchc.edu
Raloxifene HCl, a selective estrogen receptor modulator, has been shown to increase bone mineral density (BMD) and decrease biochemical markers of bone turnover in postmenopausal women without stimulatory effects on the breast and uterus. However, it is not known whether the changes in BMD and bone turnover are associated with changes at the tissue level, nor how changes with raloxifene compare with estrogen. In this randomized, double blind study, we evaluated the effects of raloxifene (Evista, 60 mg/day) or conjugated equine estrogens (CEE; Premarin, 0.625 mg/day) on bone architecture, bone turnover, and BMD. Iliac crest bone biopsies were obtained at baseline and at the end of the study after double tetracycline labeling and were analyzed for standard histomorphometric indexes. Serum and urinary biochemical markers of bone turnover were measured at baseline and at 4, 10, 18, and 24 weeks of treatment. Total body, lumbar spine, and hip BMD were measured at baseline and at the end of the study by dual energy x-ray absorptiometry.
Activation frequency and bone formation rate/bone volume were significantly decreased from baseline in the CEE, but not in the raloxifene, group. Bone mineralization did not change in either group. Most markers of bone resorption and formation decreased in both groups, but to a greater degree in the CEE group (P < .05). Total body and lumbar spine BMD increased from baseline in both groups, with a greater increase in the CEE group (P < 0.05). Hip BMD significantly increased from baseline in the raloxifene group, but the change was not different from that in the CEE group. These results suggest that raloxifene reduces bone turnover and increases bone density, although to a lesser extent than CEE. Thus, raloxifene is an alternative to CEE for the prevention and treatment of osteoporosis in postmenopausal women.
This article has been cited by other articles:
 |
|
 |
|
  C. Bramson, D. Ouellet, D. Roman, E. Randinitis, and M. J. Gardner A Single-Dose Pharmacokinetic Study of Lasofoxifene in Healthy Volunteers and Subjects With Mild and Moderate Hepatic Impairment J. Clin. Pharmacol., January 1, 2006; 46(1): 29 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gardner, A. Taylor, G. Wei, A. Calcagni Jr, B. Duncan, and A. Milton Clinical Pharmacology of Multiple Doses of Lasofoxifene in Postmenopausal Women J. Clin. Pharmacol., January 1, 2006; 46(1): 52 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Compston Bone Histomorphometry -- The Renaissance? IBMS BoneKEy, May 1, 2004; 1(5): 9 - 12. [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid, R. Eastell, I. Fogelman, J. D. Adachi, A. Rosen, C. Netelenbos, N. B. Watts, E. Seeman, A. V. Ciaccia, and M. W. Draper A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women Arch Intern Med, April 26, 2004; 164(8): 871 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Budden and M. E. Gunness Possible Mechanisms of Osteopenia in Rett Syndrome: Bone Histomorphometric Studies J Child Neurol, October 1, 2003; 18(10): 698 - 702. [Abstract] [PDF]
|
|
|
|
 |
|
 S. F Eichner, K. B Lloyd, and E. M Timpe Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment Ann. Pharmacother., May 1, 2003; 37(5): 711 - 724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Simha, J. E. Zerwekh, K. Sakhaee, and A. Garg Effect of Subcutaneous Leptin Replacement Therapy on Bone Metabolism in Patients with Generalized Lipodystrophy J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 4942 - 4945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, C. Nappi, P. Mastrantonio, G. Lombardi, A. Colao, and F. Zullo Raloxifene Administration in Women Treated with Gonadotropin-Releasing Hormone Agonist for Uterine Leiomyomas: Effects on Bone Metabolism J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4476 - 4481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Johnell, W. H. Scheele, Y. Lu, J.-Y. Reginster, A. G. Need, and E. Seeman Additive Effects of Raloxifene and Alendronate on Bone Density and Biochemical Markers of Bone Remodeling in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 985 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Jordan, S. Gapstur, and M. Morrow Selective Estrogen Receptor Modulation and Reduction in Risk of Breast Cancer, Osteoporosis, and Coronary Heart Disease J Natl Cancer Inst, October 3, 2001; 93(19): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H.-J. Hsu, W.-C. Cheng, M.-W. Jang, and K.-S. Tsai Effects of Long-Term Use of Raloxifene, a Selective Estrogen Receptor Modulator, on Thyroid Function Test Profiles Clin. Chem., October 1, 2001; 47(10): 1865 - 1867. [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Goldstein, P. Neven, L. Zhou, Y. L. Taylor, A. V. Ciaccia, and L. Plouffe Jr Raloxifene Effect on Frequency of Surgery for Pelvic Floor Relaxation Obstet. Gynecol., July 1, 2001; 98(1): 91 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Altkorn and T. Vokes Treatment of Postmenopausal Osteoporosis JAMA, March 21, 2001; 285(11): 1415 - 1418. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
